Pharmicell Co.,Ltd.
Biopharma firm in stem cell therapies, biochemicals, cell banking, and stem cell cosmetics.
005690 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 강남구 언주로 874 (신사동, 쌍봉빌딩 7층), 강남구
- Website:
- https://www.pharmicell.com/eng/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Pharmicell Co., Ltd. is a biopharmaceutical company specializing in stem cell technology. The company is a pioneer in the field, having developed and commercialized Hearticellgram®-AMI, the world's first approved stem cell therapy for acute myocardial infarction. Its business is diversified across four main segments: stem cell therapeutics, including ongoing research for conditions like liver disease; a biochemical division that conducts oligonucleotide synthesis and produces nucleosides, mPEGs, and pharmaceutical intermediates; a stem cell banking business for adult and cord blood ('Twelve' brand); and a line of cosmetics derived from stem cell culture media ('By Pharmicell lab' brand).
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Pharmicell Co.,Ltd. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
Automate Your Workflow. Get a real-time feed of all Pharmicell Co.,Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Pharmicell Co.,Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
